Preface: Coagulopathies and thrombosis: Usual and unusual causes and associations, part III

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 1, 2010, Pages 1-5

  Favaloro, Emmanuel J ^a   Lippi, Giuseppe ^b   Franchini, Massimo ^c  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING DISORDER; CAUSAL ATTRIBUTION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; EDITORIAL; HUMAN; LUNG EMBOLISM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; HEMOPHILIA A; INFLUENZA; INFLUENZA VIRUS A; KIDNEY DISEASE; OBESITY; ORTHOMYXOVIRUS INFECTION; PATHOPHYSIOLOGY; PHYSIOLOGY; SWINE; THROMBOTIC THROMBOCYTOPENIC PURPURA; WINE;

ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; BLOOD CLOTTING FACTOR 13; FIBRINOGEN; VON WILLEBRAND FACTOR;

ADAM PROTEINS; ANIMALS; BLOOD COAGULATION DISORDERS; FACTOR XIII; FIBRINOGEN; HEMOPHILIA A; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; KIDNEY DISEASES; OBESITY; ORTHOMYXOVIRIDAE INFECTIONS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SWINE; THROMBOSIS; VON WILLEBRAND FACTOR; WINE;

EID: 77951072014     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1248719     Document Type: Editorial

References (24)

1. Franchini M, Lippi G, Favaloro E J. Coagulopathies and thrombosis: usual and unusual causes and associations, Part I. Semin Thromb Hemost 2009 35 257-259
2. Lippi G, Franchini M, Favaloro E J. Coagulopathies and thrombosis: usual and unusual causes and associations, Part II. Semin Thromb Hemost 2009 35 591-596
3. Montagnana M, Favaloro E J., Franchini M, Guidi G C., Lippi G. The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis 2009 June 18 (Epub ahead of print)
4. Heit J A., Silverstein M D., Mohr D N. et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001 86 452-463
5. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008 34 747-761
6. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009 35 (4) 356-366
7. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009 35 (4) 426-438
8. Lippi G, Plebani M. Rapid diagnosis of swine-origin influenza A (H1N1) virus (S-OIV): useful or hype? Clin Chem Lab Med 2010 48 (1) 1-5
9. Lippi G, Franchini M, Favaloro E J. Unsuspected triggers of venous thromboembolismtrivial or not so trivial? Semin Thromb Hemost 2009 35 597-604
10. Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007 33 787-797 (Pubitemid 351158447)
11. Franchini M, Lippi G. Together we care: new challenges for global haemophilia treatment centers. Indian J Med Res 2009 129 345-347
12. Pengo V. Management of oral anticoagulant treatment in patients with venous thromboembolism. Semin Thromb Hemost 2006 32 781-786 (Pubitemid 44956972)
13. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009 35 515-524
14. Levi M, Hobbs F D., Jacobson A K. et al. Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. Semin Thromb Hemost 2009 35 527-542
15. Harenberg J. New anticoagulants in atrial fibrillation. Semin Thromb Hemost 2009 35 574-585
16. Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Hemost 2008 34 779-793
17. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008 34 39-57 (Pubitemid 351640881)
18. Mousa S A. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007 33 524-533
19. Laux V, Perzborn E, Kubitza D et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007 33 515-523 (Pubitemid 47105742)
20. Prandoni P, Lensing A W., Pesavento R. New strategies for the treatment of acute venous thromboembolism. Semin Thromb Hemost 2006 32 787-792 (Pubitemid 44956973)
21. Fareed J, Hoppensteadt D A., Fareed D et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008 34 58-73
22. Franchini M, Lippi G. Antagonists of activated factor X and thrombin: innovative antithrombotic agents. Curr Vasc Pharmacol 2007 5 121-128
23. Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009 35 400-406
24. Lippi G, Montagnana M, Salvagno G L., Poli G, Franchini M, Guidi G C. Influence of warfarin therapy on activated factor VII clotting activity. Blood Coagul Fibrinolysis 2006 17 221-224